Seth Harmon
Equibles does not estimate personal net worth.
Get an email with a short summary when Viridian Therapeutics, Inc.\DE publishes a filing, an earnings call transcript or a press release.
Get VRDN alertsAbout Seth Harmon
Seth Harmon is recorded as CFO at Viridian Therapeutics, Inc.\DE (VRDN). The newest filing on record that lists Seth Harmon as CFO at Viridian Therapeutics, Inc.\DE (VRDN) is dated April 17, 2026. Viridian Therapeutics, Inc.\DE reported in an 8-K filed January 10, 2025 that Seth Harmon was appointed Chief Financial Officer, effective January 1, 2025. The proxy statement of Viridian Therapeutics, Inc.\DE reports total compensation of $2,642,779 for Seth Harmon in fiscal 2025, including a base salary of $480,000. Disclosed compensation is on record for 4 fiscal years. Viridian Therapeutics, Inc.\DE is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Viridian Therapeutics, Inc.\DE includes Scott Myers (CEO and Board Member), Stephen Mahoney (CEO and Board Member), Tomas Kiselak (Chairman) and 7 others.
“On January 7, 2025, the Board of Directors of Viridian Therapeutics, Inc. (the "Company") appointed Seth Harmon to serve as the Chief Financial Officer of the Company effective as of January 1, 2025.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 17, 2026
-
Viridian Therapeutics, Inc.\DE (VRDN)
Proxy statement
Start not stated–2024-04-26
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Viridian Therapeutics, Inc.\DE
- Scott Myers CEO, Board Member
- Stephen Mahoney CEO, Board Member
- Tomas Kiselak Chairman
- Jonathan Violin COO
- Lee Rauch COO, Board Member
- Thomas Beetham COO
- Lara Meisner General Counsel
- Kristian Humer Chief Accounting Officer
- Arlene M. Morris Board Member
- Chris Cain Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Financial Officer | $480,000 | $2,642,779 |
| 2024 | Viridian Therapeutics, Inc.\DE (VRDN) | Senior Vice President, Finance and Accounting | $419,600 | $770,659 |
| 2023 | Viridian Therapeutics, Inc.\DE (VRDN) | Senior Vice President, Finance and Accounting | $241,427 | $6,548,526 |
| 2022 | Viridian Therapeutics, Inc.\DE (VRDN) | Senior Vice President, Finance and Accounting | — | — |